ONC201, defined as a superior ClpP activator, had shown promising results in the first clinical trial with refractory solid tumors [21]. Over the years, multiple clinical trials have been carried out for ONC201 in solid tumors, including the project NCT03791398, involving Phase I and Phase II...
6.0 CLINICAL TRIAL IMP Documentation Y / N /NA Version Number / Date / Missing Summary of drug arrangements Current Product Information (Full/Simplified IMPD) Current IMP Safety Information document (IB or SPC) Superseded version of Product Information Superseded version of IMP Safety Informatio...
It is important to note that for the above studies, the selection criteria differed, ranging41 from women undergoing their first IVF2,8 to those having 2 or more failed full IVF/ICSI c ycles42,43. RCTs utilizing mid-luteal phase LEI protocols suggest a clinical benefit. Nas- ...
as already demonstrated in OI using mismatches in the hammerhead ribozymes binding arm as well as in other diseases.33 The two most promising siRNAs determined by the in vitro luciferase assay, namely e and f, were also efficient against the full- length collagen gene in Brtl primary fibroblas...